Kestra Medical Technologies, Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian Webster
- Full Time Employees
- 443
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3933 Lake Washington Blvd NE Kirkland WA United States of America 98033
- IPO Date
- Mar 6, 2025
- CIK
- 0001877184
- Website
- kestramedical.com
- Similar Companies
- Business
- Kestra Medical Technologies, Ltd. (KMTS) develops and commercializes wearable medical devices and digital healthcare solutions focused on protecting patients at risk of sudden cardiac arrest through intuitive, intelligent, and connected diagnostic and therapeutic technologies; its core Cardiac Recovery System platform integrates the ASSURE Wearable Cardioverter Defibrillator (WCD) for continuous monitoring and automatic defibrillation of ventricular arrhythmias, the Kestra CareStation cloud-based remote patient data platform for provider oversight and notifications, the ASSURE patient mobile application for self-management, activity tracking, educational content, and data transmission, and the ASSURE Wearable ECG for post-WCD monitoring using the same SensorFit garment and algorithms. Kestra Medical Technologies operates primarily in the cardiovascular disease segment, targeting heart failure patients and those with low left ventricular ejection fraction awaiting therapy eligibility; it serves healthcare providers including over 550 hospitals across the United States with in-network payer coverage reaching 285 million lives, and maintains a presence in Ireland. Founded in 2014 and headquartered in Kirkland, Washington, the company employs approximately 300 people and has grown its clinical registry beyond 20,000 patients. In July 2024, Kestra Medical Technologies completed an oversubscribed $196 million financing round co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds, with participation from T. Rowe Price Investment Management, Eventide Asset Management, Gilmartin Capital, Bain Capital, and Endeavour Vision, funding commercial expansion of the ASSURE system; in March 2025, it priced an upsized initial public offering on Nasdaq at $17 per share, raising $202 million; fiscal year 2025 delivered record revenue of $59.8 million, up 115% year-over-year, with 3,903 ASSURE prescriptions in Q4 alone (up 43%) and gross margins expanding to 40.5%, alongside commercial team growth to 80 sales territories and FY2026 revenue guidance of $85 million.
Company News
Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – Should You Buy?
Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies
Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Miss
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
Kestra Medical Technologies Q1 Earnings Call Highlights
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Kestra Names Daniel Finney Vice President of Research & Development
Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
Here Are Monday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Apple, Dicks Sporting Goods, Domino’s Pizza, Doximity, NetApp, SanDisk, Trade Desk, and More
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?
Kestra Medical Technologies, Ltd. (KMTS) Q4 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates
Kestra Medical Technologies Q4 Earnings Call Highlights